Codagenix
Clinical-stage biotechnology company using computational and synthetic biology tools to rationally design live-attenuated vaccines with improved safety and efficacy profiles.
Notes
Codagenix is a clinical-stage biotechnology company pioneering the use of computational and synthetic biology to design a new generation of live-attenuated vaccines. Their proprietary SAVE™ (Synthetic Attenuated Virus Engineering) platform uses codon deoptimization to create weakened viruses that cannot revert to virulence, addressing a key safety concern with traditional live vaccines.
The company is developing vaccines for respiratory syncytial virus (RSV), influenza, and other infectious diseases, leveraging their platform to create vaccines that provide robust immune responses while maintaining an improved safety profile.
Team
- J. Robert Coleman, Ph.D. - Co-founder & Chief Executive Officer
- LinkedIn: linkedin.com/in/jrobertcoleman
- Steffen Mueller, Ph.D. - Co-founder & Chief Scientific Officer
- Eckard Wimmer, Ph.D. - Scientific Founder (Stony Brook University)
Additional Research Findings
- SAVE™ (Synthetic Attenuated Virus Engineering) platform
- Codon deoptimization for vaccine safety
- Live-attenuated vaccine technology
- RSV and influenza vaccine candidates
- Stony Brook University spinout
- Headquarters in Farmingdale, New York
- Clinical-stage vaccine development
- Computational approach to vaccine design
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Adjuvant Capital | Washington, DC, USA | biotech-focused | seedseries-a+3 | 16 |